{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-026398","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.961082+00:00","generated_at":"2026-05-15T14:52:10.621467+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elutia Q4 revenue $3.3M (+16% YoY); NXT-41 510(k) submitted; cash $36.4M","bullets":["Q4 2025 net sales from continuing ops $3.3M, up 16% YoY; adjusted gross margin 66.8%.","Full year net sales $12.3M; net loss from continuing ops $15.9M; net income $53.4M includes gain on BioEnvelope sale.","Submitted 510(k) for NXT-41 base biologic matrix to FDA; clearance expected H2 2026; full NXT-41x clearance in 1H27.","Closed $88M BioEnvelope sale to Boston Scientific; repaid $26.9M debt; cash $36.4M plus $8M escrow.","Initiated strategic review for SimpliDerm product line to focus on NXT-41x launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-026398","json":"https://secwatch.observer/filing/0001104659-26-026398.json","markdown":"https://secwatch.observer/filing/0001104659-26-026398.md","text":"https://secwatch.observer/filing/0001104659-26-026398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465926026398/0001104659-26-026398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465926026398/elut-20260303x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:52:10.621467+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}